WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016056701) ANTIOBESITY COMPOSITION CONTAINING THIODIGALACTOSIDE AS ACTIVE INGREDIENT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/056701    International Application No.:    PCT/KR2014/011223
Publication Date: 14.04.2016 International Filing Date: 20.11.2014
IPC:
A61K 31/7016 (2006.01), A61K 31/70 (2006.01), A61P 3/04 (2006.01)
Applicants: INDUSTRY ACADEMIC COOPERATION FOUNDATION DAEGU UNIVERSITY [KR/KR]; (Daegu University) 201 Daegudaero Jillyang-eup Gyeongsan-si Gyeongsangbuk-do 712-714 (KR)
Inventors: YUN, Jong Won; (KR)
Agent: LEE, Duck-Rog; (KR)
Priority Data:
10-2014-0136749 10.10.2014 KR
Title (EN) ANTIOBESITY COMPOSITION CONTAINING THIODIGALACTOSIDE AS ACTIVE INGREDIENT
(FR) COMPOSITION CONTRE L'OBÉSITÉ CONTENANT UN THIODIGALACTOSIDE EN TANT QUE PRINCIPE ACTIF
(KO) 티오디갈락토사이드를 유효성분으로 함유하는 항비만 조성물
Abstract: front page image
(EN)The present invention relates to a method for preparing an antiobesity composition containing thiodigalactoside (TDG). Rats are divided into three groups, a control group with a normal diet (ND), a high-fat diet control (HFD) group, and an HFD group treated with thiodigalactoside, and then the comparision of the body weight, diet efficiency, and fat tissue and the comparative measurement of expressions of energy consumption-related genes and proteins, which are used in the lipogenesis and lipolysis in fat tissues (WAT, BAT) and liver tissues, were conducted. In addition, the degree of fat accumulation in lgals1-knockdown cells obtained using 3T3-L1 and HIB1B preadipocytes was comparatively measured and evaluated, through mRNA, protein levels, ORO staining, and TG content. Both animal experimental results and cell-level experimental results confirmed that the TDG treatment selectively inhibits galectin-1 expression, leading to suppressing fat synthesis and promoting fat consumption, and thus the present invention has an excellent effect of providing a novel antiobesity composition exhibiting the same effect in lactose, lactobionic acid, lactulose amines, anginex, davanat, and α-galactomannan, which are galectin-1 inhibitor-like compounds, other than TDG.
(FR)La présente invention concerne un procédé de préparation d'une composition contre l'obésité contenant un thiodigalactoside (TDG). Des rats ont été divisés en trois groupes, un groupe témoin recevant un régime alimentaire normal (ND), un groupe témoin recevant un régime à forte teneur en matière grasse (HFD), et un groupe HFD traité avec le thiodigalactoside, après quoi ont été effectuées des comparaisons du poids corporel, de l'efficacité du régime alimentaire et du tissu adipeux, ainsi que des mesures comparatives de l'expression de gènes et de protéines liés à la consommation d'énergie, qui sont utilisés au cours de la lipogenèse et la lipolyse dans les tissus adipeux (WAT, BAT) et les tissus du foie. De plus, le degré de l'accumulation de graisse dans cellules inactivées pour lgals1 obtenues à partir de pré-adipocytes 3T3-L1 et HIB1B a été comparativement mesuré et évalué, en utilisant l'ARNm, les niveaux de protéines, la coloration Oil Red O, et le contenu en TG. Aussi bien les résultats expérimentaux provenant des animaux que les résultats expérimentaux obtenus au niveau cellulaire ont confirmés que le traitement par TDG inhibait sélectivement l'expression de la galectine-1, conduisant à l'inhibition de la synthèse de graisse et favorisant l'utilisation de la graisse, et, par conséquent, la présente invention a le grand intérêt de fournir une nouvelle composition contre l'obésité présentant le même effet que le lactose, l'acide lactobionique, les amines de lactulose, Anginex, Davanat et l'alpha-galactomannane, qui sont des composés de type inhibiteur de la galectine-1 autre que le TDG.
(KO)본 발명은 티오디갈락토사이드(thiodigalactoside:TDG)를 함유하는 항비만 조성물을 제공하는 방법으로 래트를 정상식이대조군(ND), 고지방 식이 조절군(HFD), 티오디갈락토사이드를 처리한 HFD군의 3그룹으로 구분해 체중, 식이효율, 지방조직의 무게를 비교하고 지방조직 (WAT, BAT) 및 간조직에서 지방생성 및 분해에 사용되는 에너지 소비관련 유전자 및 단백질들의 발현을 비교 측정을 하였다. 또한 3T3-L1 및 HIB1B 지방선구세포를 이용해 lgals1 유전자가 결손 (Knockdown)된 세포를 mRNA, 단백질 수준과 ORO 염색 및 TG 함량을 통해 지방축적 정도를 비교 측정하여 평가하였다. 동물실험결과와 세포수준의 실험결과 모두 TDG처리가 갈렉틴-1 발현을 선택적으로 저해하는 것에 의해 지방합성을 억제하고 지방소모를 촉진하는 효과를 확인하여 TDG외에 다른 갈렉틴-1 억제제로서 유사 화합물 lactose, lactobionic acid, lactulose amines, anginex, davanat 및 α-galactomannan에도 동일한 효과를 나타내는 신규한 항비만 조성물을 제공하는 뛰어난 효과가 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)